SPOTLIGHT: Takeda buying out TAP partner

The wire services have been buzzing with reports that Takeda is close to a deal to buy out Abbott Laboratories' 50 percent stake in TAP Pharmaceutical, a joint venture. The stake is worth anywhere from $3 billion to $5 billion and would boost Takeda's rankings among global pharma players from 17th to 14th. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.